Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy

Immix Biopharma

28/01/2026 14:01

** Shares of Immix Biopharma IMMX.O rise 4.4% to $6.20 premarket

** Co says the U.S. FDA has granted a 'breakthrough therapy' designation to NXC-201 for the treatment of AL Amyloidosis, a type of blood disorder

** A breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need

** Says the tag is based on mid-stage trial results of NXC-201

** Co plans to submit marketing application for the therapy this year

** AL amyloidosis is a rare and serious blood-related disorder where abnormal proteins build up in vital organs, interfering with their function

** As of last close, stock has more than tripled in the last 12 months

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))